Western Wealth Management LLC Acquires 4,068 Shares of Gilead Sciences, Inc. $GILD

Western Wealth Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 104.8% during the first quarter, Holdings Channel.com reports. The firm owned 7,949 shares of the biopharmaceutical company’s stock after acquiring an additional 4,068 shares during the period. Western Wealth Management LLC’s holdings in Gilead Sciences were worth $1,108,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC increased its position in shares of Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC raised its holdings in Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 674 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GILD shares. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday. Finally, Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 20th. Twenty-four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Stock Performance

GILD stock opened at $135.87 on Thursday. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The firm has a market cap of $168.47 billion, a price-to-earnings ratio of -50.89 and a beta of 0.32. The business’s fifty day simple moving average is $129.75 and its two-hundred day simple moving average is $136.42. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.01 earnings per share. Analysts predict that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the transaction, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 82,000 shares of company stock worth $10,641,790 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead is partnering with Nucleai to deploy AI-powered tissue analytics across its global antibody-drug conjugate programs. The technology could accelerate biomarker discovery, standardize tumor-sample analysis and improve precision-oncology development, potentially strengthening Gilead’s longer-term pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Gilead exercised an option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment to its partner. The move expands Gilead’s oncology assets and signals continued investment in potential next-generation cancer treatments, although the program remains early stage. MacroGenics Announces $10 Million Milestone Following Gilead License
• Positive Sentiment: Analysts cited a consensus price target of $158.04, indicating potential upside relative to recent trading levels and continued confidence among covering analysts. Gilead Receives $158.04 Consensus Target Price
• Positive Sentiment: Gilead’s second-quarter revenue rose approximately 10% year over year to $7.8 billion and exceeded expectations. The reported loss was primarily affected by an $11.2 billion one-time acquired in-process research and development write-off, while adjusted results were better than consensus. GILD Attractive Biotech Stock With Solid Base Revenue Growth
• Neutral Sentiment: Unusually heavy call-option buying points to increased bullish trading interest, but options activity is speculative and does not by itself change Gilead’s fundamentals.
• Neutral Sentiment: Coverage of Gilead’s second-quarter earnings call may provide additional details on pipeline progress and management priorities, though no specific new financial catalyst was provided in the supplied report. Analyst Questions From Gilead’s Q2 Earnings Call
• Negative Sentiment: Erste Group Bank slightly reduced its FY2026 EPS forecast to a $0.75 loss from a $0.74 loss and trimmed its FY2027 estimate to $9.57 from $9.59. Although the changes are small, they indicate mildly softer expectations and contrast with the $0.50 consensus loss forecast for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.